HANWHA SOLUTIONS CORP.

DUBLIN, Dec. 19, 2022 /PRNewswire/ -- The "Global Biosimilars Partnering Terms and Agreements 2010 to 2022" report has been added to ResearchAndMarkets.com's offering. The Global Biosimilars Partnering Terms and Agreements 2010 to 2022 report provides an understanding and access to 190 biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter biosimilars partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors biosimilars technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. This report contains links to online copies of actual biosimilars deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. The initial chapters of this report provide an orientation of biosimilars dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in biosimilars dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading biosimilars deals since 2010. Deals are listed by headline value, signed by big pharma, most active biosimilars dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 25 most active companies in biosimilars dealmaking with a brief summary followed by a comprehensive listing of biosimilars deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 5 provides a comprehensive and detailed review of biosimilars partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive and detailed review of biosimilars partnering deals signed and announced since Jan 2010. The chapter is organized by specific biosimilars technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. In addition, a comprehensive appendix is provided organized by biosimilars partnering company A-Z, deal type definitions and biosimilars partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Analyzing actual company deals and agreements allows assessment of the following: What is actually granted by the agreement to the partner company? What exclusivity is granted? What are the precise rights granted or optioned? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Global Biosimilars Partnering Terms and Agreements 2010 to 2022 includes: Trends in biosimilars dealmaking in the biopharma industry since 2010 Access to headline, upfront, milestone and royalty data Access to over 190 biosimilars deal records and contract documents where available The leading biosimilar deals by value since 2010 Most active biosimilars dealmakers since 2010 The leading biosimilars partnering resources In Global Biosimilars Partnering Terms and Agreements 2010 to 2022, the available contracts are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific therapy and technology target Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in biosimilars dealmaking 2.1. Introduction 2.2. Biosimilars partnering over the years 2.3. Most active biosimilars dealmakers 2.4. Biosimilars partnering by deal type 2.5. Biosimilars partnering by therapy area 2.6. Deal terms for biosimilars partnering 2.6.1 Biosimilars partnering headline values 2.6.2 Biosimilars deal upfront payments 2.6.3 Biosimilars deal milestone payments 2.6.4 Biosimilars royalty rates Chapter 3 - Leading biosimilars deals 3.1. Introduction 3.2. Top biosimilars deals by value Chapter 4 - Most active biosimilars dealmakers 4.1. Introduction 4.2. Most active biosimilars dealmakers 4.3. Most active biosimilars partnering company profiles Chapter 5 - Biosimilars contracts dealmaking directory 5.1. Introduction 5.2. Biosimilars contracts dealmaking directory Chapter 6 - Biosimilars dealmaking by technology type Appendices Appendix 1 - Biosimilars deals by company A-Z Appendix 2 - Biosimilars deals by stage of development Appendix 3 - Biosimilars deals by deal type Appendix 4 - Biosimilars deals by therapy area Appendix 5 - Appendix 6 - Recent report titles from Companies Mentioned 3SBio 180 Life Sciences Abbvie Abreos Biosciences Abzena Accord Healthcare Aceno Biotherapeutics AdAlta AET Biotech Aetos Biologics AffaMed Therapeutics Agila Specialties AIT Bioscience Algorithme Pharma Holdings Alteogen Altiora Alvogen Alvotech Amedica Amgen Amneal Pharmaceuticals Arecor Avid Bioservices Axantia Back-A-Line Bacterin International Baxalta Baxter International BeiGene Bio-Manguinhos/Fiocruz Bio-Thera Solutions Biocnd Biocon Bioeq IP Bio Farma Biogen Biooutsource BiosanaPharma BioSavita BioSciencesCorp Bioton BioXpress Boehringer Ingelheim Bolt Biotherapeutics Boston Oncology Bruker C-Bridge Capital Catalent CEA-Leti Celares Celerion Cellectis Celltrion Changchun High & New Technology Industries Chemo Sa Lugano Chungnam National University Cipla CJ Corp Clinigen Cobra Biologics Coherus Biosciences Compass Biotechnologies Concord Biosciences Cook Pharmica CR Pharma Daiichi Sankyo Diabeloop DM Corporation Dong-A ST Dr. Reddy's Laboratories Dyadic International EirGenix EMD Millipore Enzene Biosciences Epirus Biopharmaceuticals Epivax European Commission Evercyte Evotec Ewopharma Formosa Pharmaceuticals Formycon Fujifilm Fujifilm Kyowa Kirin Biologics Fuji Pharma GC Pharma Gedeon Richter GE Healthcare Genentech Genhelix Biopharmaceutical Genor Biopharma GenScript ProBio Gerresheimer Hadasit Medical Research Services and Development Hanwha Chemical Helvetic Biopharma Henlius Biotech Hikma Pharmaceuticals Hoffmann La Roche Horizon 2020 Hospira Innovent Biologics Intas Pharmaceuticals inVentiv Health Ipca Laboratories Ipsen Jacobson Pharma JAMP Pharma Group JHL Biotech Kamada Karolinska Institute Kemwell BioPharma Kymos Pharma Services Kyowa Hakko Kirin Laboratorios Liomont LABORATORIOS SAVAL Ligacept Livzon Mabpharm Lupin M+W Group Mab-Venture Biopharma Mabion mAbXience Medicago Medicure Medipolis Meiji Seika Merck and Co Merck BioVentures Merck KGaA Merck Serono MGC Diagnostics Ministry of Health (Brazil) Mithra Pharmaceuticals Mitsubishi Chemical Mochida Pharmaceutical Momenta Pharmaceuticals Mundipharma Mylan Laboratories Mylan Pharmaceuticals Nan Fung Group NanoLock Natco Pharmaceuticals National Cancer Institute National Comprehensive Cancer Network (NCCN) NCPC GeneTech Neoletix Biotechnology NeuClone Nora Pharma Novo Nordisk Ocumension Therapeutics Oncobiologics ORF Genetics Orox Pharmaceuticals Orygen Biotecnologia Pall Corporation Pangen Biotech Parexel PBS Biotech Perfinity Biosciences Pfenex Pfizer Pharmapark PharmaPraxis PlantForm PlantPraxis Biotecnologia Polpharma Portal Instruments PPD PRA Health Sciences Premier Inc Premier Research Prestige BioPharma ProBioGen PT Etana Biotechnologies Qilu Pharmaceutical Quanta BioDesign QuiaPEG Pharmaceuticals For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

前   言   靶向蛋白降解（Targeted protein degradation, TPD）是药物发现领域一种极具前景的策略。蛋白质水解靶向嵌合体（PROTAC）是TPD策略最具代表性的技术，其原理是利用泛素-蛋白酶体系统（UPS）降解含有胞质结构域的靶蛋白[1]（图1）。除PROTAC外，基于溶酶体的TPD策略（LYTAC）、基于抗体的PROTAC（AbTAC）和自噬靶向嵌合体（AUTOTAC）已在降解膜蛋白、细胞外蛋白和蛋白聚体方面取得成功，从而大大扩大了靶蛋白的范围。图1：泛素-蛋白酶体系统（UPS）[1]然而，PROTAC的应用仅限于含有可连接位点的胞质结构域的蛋白质靶标，结合靶蛋白的配体通常通过高通量筛选、设计来确定，对于缺乏明确活性位点的蛋白质，开发小分子配体既困难又耗时[2]。令人振奋的是，最近，基于核酸的策略开辟了降解蛋白质靶标的新途径。基于核酸的TPD有以下优点：一是扩大了细胞内靶蛋白的范围。利用核酸基序作为弹头的PROTAC已成功应用于降解缺乏活性配体结合位点的蛋白质，包括RNA结合蛋白（RBPs）、转录因子（TFs）和G-四联体（G4）结合蛋白。二是可用于开发膜蛋白靶向降解的平台（例如，双特异性适体嵌合体）。核酸适体还能当作靶向递送工具，用于肿瘤的特异性靶向降解。三是核酸基序可以作为靶向降解的底物治疗RNA疾病。新出现的RNA降解技术——核糖核酸酶靶向嵌合体（RIBOTAC）——表明PROTAC的嵌合降解原理已扩展到RNA领域。本篇综述介绍了基于核酸的TPD新策略，以及核酸（RNA）靶向降解的新进展[3]。作者 | 梨子君01基于核酸的TPD新策略      1）靶向RNA结合蛋白RNA结合蛋白（RBPs）属于一类特殊的核酸相互作用因子，参与各种重要的细胞过程。然而，大多数RBP缺乏能有效结合小分子的传统酶袋，其同源蛋白结构域的存在也会导致小分子在细胞内活性受限。针对以上问题，Hall的团队开发了一种RNA-PROTAC，利用短RNA模拟物——与RBP的RNA共有结合元件（RBE）同序——作为弹头结合RBE和E3招募肽，从而介导蛋白酶体降解[4]（图2）。第一个RNA-PROTACs被设计用于降解两种RBP：干细胞因子LIN28（Lin28A）和剪接因子RBFOX1。尽管RNA-PROTAC是一种令人振奋的降解RBP的方法，但它仍存在一些缺点，如RNA寡聚体在体内不稳定，以及需要RNA二级结构才能与RBP正确相互作用。图2：RNA-PROTACs设计策略示意图     2）靶向转录因子转录因子（TFs）是一种DNA结合蛋白，与特定的DNA序列相互作用，控制染色质和转录，是许多疾病，特别是癌症的重要驱动因素，近300个致癌TFs约占所有已知癌基因的20%。然而，大多数致癌TFs没有天然的配体结合袋，长期以来被认为是不可成药的靶点。虽然近期已发展出针对TFs的TPD技术，但传统的基于抑制剂的降解策略并不适用于所有TFs目标。为了解决这个问题，已经出现了多种针对TFs的基于核酸的降解剂，如下表所示（表1）。表1：基于小分子和核酸的TFs降解剂实例Crews的团队开发了转录因子靶向嵌合体（TRAFTACs），通过选择细胞降解机制，诱导靶向TF降解。TRAFTAC是异双功能嵌合寡核苷酸，由两个部分组成：结合靶标TF的双链DNA和结合dCas9-Halotag7融合蛋白的CRISPR-RNA。TRAFTAC通过dCas9HT7将VHL E3连接酶复合物招募到靶标TF附近，然后，TF被用泛素标记并被UPS降解。Wei和Jin的团队开发TF-PROTACs通用平台（图3A），将叠氮修饰的DNA低聚物（N3-ODN）用各种Linker与双环辛烷修饰的VHL配体（VHLL-XBCN）组装，实现TF的选择性降解（图3B）。图3：TF-PROTACs的设计策略（A）和代表化学结构（B）  3）靶向G4结合蛋白G-四联体（G4s）是G-四联体是富含鸟嘌呤碱基的一种特殊四链核酸结构，通过Hoogsteen-氢键结合形成四分体的正方形平面结构，而两个或更多个鸟嘌呤四分体在阳离子（尤其是钾）配位的情况下，通过π-π堆叠形成G-四联体结构。据报道，G4s存在于许多真核细胞的基因组中，参与了很多关键的生物过程和多种人类遗传疾病，也是是近年来新发现的抗癌药物重要靶点[5]。Phan的团队设计了第一个G4-PROTAC，使用G4作为弹头，靶向降解G4结合蛋白RHAU（图4A），该蛋白是肌萎缩侧索硬化症（ALS）的潜在治疗靶点。鉴于RHAU优先与高亲和力的全平行链G4结合，采用全平行链G4拓扑结构的序列TT（GGGT)4 （称为T95−2T）作为弹头。通过点击反应将叠氮修饰的E3连接酶招募者与5′端的T95−2T连接，组装成G4-PROTAC（图4B）。图4：G4-PROTACs的设计策略（A）和代表化学结构（B）  4）靶向膜相关蛋白通过双特异性适体嵌合体可以靶向降解膜相关蛋白。适体也称为化学抗体，是具有独特三维结构的单链DNA或RNA寡核苷酸，能够与同源分子靶标特异结合。与其他靶向载体相比，核酸适体具有制备简单、合成精确、易于化学修饰、稳定性好、特异性高、良好的物理化学性质以及良好的体内安全性等优点，但免疫原性有限。近年来，适体已成为治疗药物的有效识别元件和递送工具，通常是通过网状蛋白介导的内吞途径。Han的团队开发了双特异性适体嵌合体，成为第一个基于适体的靶向降解膜相关蛋白的技术。双特异性适体嵌合体是一种双功能分子，具有基本结构“适体1-Linker-适体2”（A1-L-A2），其中A1和A2分别与IGFIIR和膜相关蛋白特异性结合（图5A）。广泛表达的IGFIIR是细胞表面一种典型的溶酶体靶向受体，当双特异性适体嵌合体结合时，IGFIIR与其货物一起内吞，介导膜相关蛋白转移到溶酶体进行降解。该技术已在两种膜受体——间充质上皮转化（Met）受体和酪氨酸激酶样蛋白7（PTK-7）——进行有效验证（图5B）。图5：双特异性适体嵌合体的设计策略（A）和代表化学结构（B）  5）特异性靶向肿瘤适体已被广泛作为肿瘤识别元件，应用于靶向癌症治疗[6]。其中，核仁适体AS1411是一种人工合成的富含26碱基鸟嘌呤的单链DNA寡核苷酸，已被深入研究并被证实具有良好的肿瘤靶向性和安全性，适合作为肿瘤靶向元件用于生化研究和药物开发。Wang的团队开发了适体-PROTAC偶联物（APCs），利用适体良好的物理化学性质和高特异性，提高了传统PROTAC的特异性和抗肿瘤效果，APC由三个元件组成：PROTAC元件（介导E3连接酶和蛋白互作，催化蛋白泛素化降解）；适体元件（作为靶向肿瘤的递送载体）；可切割的Linker（使原始PROTAC在细胞内靶向释放）。AS1411除了作为肿瘤特异性识别元件和PROTAC的递送载体外，还能够作为靶向核仁素的弹头（图6）。细胞表面的核仁素已在多种癌症中被发现，在调节癌症进展中发挥重要作用。Tan的团队将DBCO标记的AS1411连接到叠氮修饰的VHL结合配体上，从而开发出第一个核仁素降解剂。图6：适体-PROTACs的设计策略02核酸靶向降解新进展绝大多数靶向降解技术都是针对蛋白质的。振奋人心的是，Disney的团队已经开发出几种有针对性的RNA降解方法，其中一种新的策略称为RIBOTAC[7]。RIBOTAC由一个RNA结合小分子和一个核糖核酸酶（RNase）L招募结构组成（图7）。RNase L在细胞中以不活跃单体形式普遍而微量表达，当免疫系统被激活时，潜伏的RNase L被上调并自身二聚化激活，随后裂解含有UU、UA、AU、AA和UG二聚体的胞质RNA。RNA降解导致翻译停滞，从而抑制蛋白质合成和病毒复制。总之，RIBOTAC是一种新的化学程序，通过动员局部先天免疫反应，实现对目标RNA的选择性切割和降解。与TPD相比，核酸靶向降解还处于起步阶段。图7：RIBOTAC设计策略结  语目前，基于核酸的TPD策略已经引起了广泛的关注，大大扩展了靶标蛋白的范围，并且具有制备简单、合成精确、特异性高、效高率和毒性低的优势，现已经开发出几个技术平台，如下表所示（表2）。表2：基于小分子和核酸的TFs降解剂实例尽管基于核酸的TPD策略进展飞速，但仍存在一些挑战。一是寡核苷酸的不稳定性可能会限制相应的嵌合体在体内的应用；二是寡核苷酸的不稳定性和负电荷导致需要其他递送方式才能进入细胞；三是寡核苷酸的快速降解可能导致不利的药代动力学缺点。总之，长路漫漫，基于核酸的嵌合降解剂应用于临床还需要更深入的探索研究。[1] Gu S, Cui D, Chen X, Xiong X, Zhao Y. PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery. Bioessays. 2018;40(4):e1700247. doi:10.1002/bies.201700247.[2] Samarasinghe KTG, Jaime-Figueroa S, Burgess M, et al. Targeted degradation of transcription factors by TRAFTACs: TRAnscription Factor TArgeting Chimeras. Cell Chem Biol. 2021;28(5):648-661.e5. doi:10.1016/j.chembiol.2021.03.011[3] Wang W, He S, Dong G, Sheng C. Nucleic-Acid-Based Targeted Degradation in Drug Discovery. J Med Chem. 2022;65(15):10217-10232. doi:10.1021/acs.jmedchem.2c00875.[4] Ghidini A, Cléry A, Halloy F, Allain FHT, Hall J. RNA-PROTACs: Degraders of RNA-Binding Proteins. Angew Chem Int Ed Engl. 2021;60(6):3163-3169. doi:10.1002/anie.202012330.[5] Balasubramanian S, Hurley LH, Neidle S. Targeting G-quadruplexes in gene promoters: a novel anticancer strategy?. Nat Rev Drug Discov. 2011;10(4):261-275. doi:10.1038/nrd3428.[6] Nimjee SM, White RR, Becker RC, Sullenger BA. Aptamers as Therapeutics. Annu Rev Pharmacol Toxicol. 2017;57:61-79. doi:10.1146/annurev-pharmtox-010716-104558.[7] Costales MG, Matsumoto Y, Velagapudi SP, Disney MD. Small Molecule Targeted Recruitment of a Nuclease to RNA. J Am Chem Soc. 2018;140(22):6741-6744. doi:10.1021/jacs.8b01233.扫码加入BiG生物创新社读者交流群，分享、交流纯粹的行业知识，非诚勿扰！BiGScientific Driven, Making Impact!创新生态丨医药论坛丨行业分析媒体公关丨BiG Webinar联系我们商务：Max   18662346610媒体：Kathy 17621909690

Displays at JEC World 2022 included (top left, clockwise) Hanwha Solutions Neptune CFRP hydrogen storage tank, GBar composite rebar, 3DiTex thermoplastic CFRP bike frame and a motorcycle brake cover using Bcomp flax fiber fabric in an epoxy composite overmolded with CF/PA in a one-shot process using a CONEXUS layer by KTM e-technologies. Photo Credit: CW. More sustainable, automated resin injection Techni-Modul Engineering (Coudes, France) highlighted its automated Smart Injection system for resin transfer molding (RTM) small parts. Resin is directly injected into the mold, infusing dry preforms without conventional tubing, which eliminates these consumables, the waste resin they store and required cleaning. Benefits claimed versus standard injection systems include: 50% labor reduction (15 vs. 30 minutes), 89% consumables reduction (€6 vs. €55) and 80% resin waste reduction (40 vs. 200 grams). Industrialized performance parts production, integrated electronics Biontec (Gallen, Switzerland) designs and manufactures high-performance composites using tailored fiber placement (TFP) and RTM. Production volumes range from 100 to 100,000 parts/year. The company is on its fourth generation of carbon fiber-reinforced polymer (CFRP) bike brake levers and clamps, which use automated stitched preforms that enable reinforced, molded-in holes and 1,200 parts per week. Biontec also showed off a laser scanner drone used for construction sites that features molded-in LEDs, antennas and cables for radar modules and radiolucent composite windows for GNNS antennas, reducing weight and increasing durability and performance. Biontec carbon fiber composite parts for bike lever (left, center) and laser scanner drone (right). Photo Credit: CW Novel automatization for 3D composite tubular/hollow structures 3DiTex (Canéjan, France) is a startup co-founded by Bertrand Laine — previously technical director for RT2i and currently CTO for NOBRAK — together with Aymeric AZRAN (CEO of NOBRAK). Its patented technology reportedly produces multilayer hollow or tubular structures that can be formed into complex shapes as preforms, during molding or thermoformed after consolidation. This technology includes machines capable of continuously producing textiles (>1 meter per minute) as well as algorithms to automate the transformation of CAD object geometry into a machine program with optimized topological trajectories. 3DiTex is targeting thermoplastic composite tapes to dramatically reduce cost, enabling new mass production applications for composites, up to 100,000 parts/year, as well as future use of bio-based matrix and/or fiber materials for improved sustainability. It is also working with other materials like ceramic fiber tapes to produce ceramic matrix composite (CMC) parts. AFP for the masses Carbon Axis (La Rochelle, France) has developed the XCell turnkey automated fiber placement (AFP) cell for SMEs who don’t have robotic skills in-house. Its compact AFP head sits within a temperature- and humidity-controlled cell with a creel below to store the towpreg and slit prepreg tape it uses to create preforms up to 1 x 0.5 x 0.5 meter. The whole system measures 1.6 x 1.6 x 2 meters and can place two 5- to 15-millimeter-wide tows/tapes at minimum lengths with angular cuts (between -45° and +45°) not typically seen in large AFP machines, offering minimized waste and automated, net-shape preforms for small parts manufacturing. The XLay all-in-one software solution integrates part design, layup design, robot simulation and robot coding for a turnkey, reportedly ready- and easy-to-use system, priced at roughly $200,000. See the XCell in action in this March 2022 video. Photo Credit: CW Continuous fiber additive manufacturing of high-volume, high-quality parts 9T Labs Fusion Module demonstrated at JEC World 2022. Photo Credit: CW 9T Labs (Zurich, Switzerland) demonstrated its Build Module and Fusion Module for 3D-printed continuous fiber parts with up to 60% fiber volume and <1% voids. CW’s focus was the Fusion Module, which can apply temperature and pressure up to 400°C and 20 bar, welding multiple printed preforms into single, function-integrated parts with superior surface finish. The system architecture enables connecting sensors for continuous process monitoring and control. The company is developing/preparing to publicize applications in aerospace (interior components, brackets, and engine components), advanced air mobility (rib stiffeners for wings), medical (surgical instruments), luxury (watchmaking, eyewear) and human exoskeletons (ergonomic support for lifting heavy loads). 9T Labs has delivered commercial systems to research centers/universities, aerospace Tier 1 suppliers and the metal forming industry via Setforge, see . Revolutionizing composites repair and production with induction heating Photo Credit: CW Msquare (Stuttgart, Germany) is a spin-off from the German Aerospace Center (DLR) advancing the use of induction heating for composites repair, heated tooling, parts preforming and production. It also offers resistance heating and hot air fan solutions for applications where induction is less optimal, such as in-field repairs to wind blades. On display at JEC were Msqaure’s variety of controllers, including multi-zone hot bonders and compact, smart/multitasking RedZero units. Its FlexIn Heat induction blankets induce eddy currents in thin, metal sheets placed only where heat is needed. Temperatures up to 400°C are applied almost immediately and homogeneously for fast heating and cooling without the need for equilibrium-establishing dwells. FlexinHeat can also be applied to platens and tools, reducing energy use by >50% versus cartridge heaters while dropping cycle times significantly. Watch CW for more about this technology including the September 2022 issue. Thermoplastic composite floor beam for the MFFD Mikrosam (Prilep, Macedonia) showcased a thermoplastic CFRP floorbeam developed in a two-year project with GKN Fokker (Hoogeveen, Netherlands), the project leader for STUNNING (SmarT mUlti-fuNctionNal and INtegrated thermoplastic fuselaGe), which is constructing the lower fuselage section of the all-thermoplastic, 8-meter-long, 4-meter-diameter Clean Sky 2 Multifunctional Fuselage Demonstrator (MFFD). GKN Fokker has installed a Mikrosam eight-axis robotic AFP machine, slitting equipment for thermoplastic prepregs and a custom-engineered thermoplastic consolidating machine. Mikrosam used its in-house systems to demonstrate floor beam production capability to GKN Fokker and produced the parts exhibited at JEC. Watch for more details in CW’s October 2022 issue. Photo Credit: CW Photo Credit: CW Resin infused rudder flap passes the test FiberCore Europe (Rotterdam, Netherlands) displayed a resin infused, glass fiber-reinforced composite rudder flap developed in the RAMSSES project. The 1:6 scale demonstrator was tested successfully to 225% of ultimate design load. The design is aimed at ~400-meter-long container ships and offers 30% weight savings versus steel and double the lifetime. Read more about RAMSSES, the InfraCore helideck and how this technology is helping remove barriers to lightweighting ships. Composite solar cells Photo Credit: CW at JEC World 2022. Porcher Industries (Badinières, France) displayed a composite solar panel developed in collaboration with the French Alternative Energies and Atomic Energy Commission (CEA). The solar cell replaces the heavy and impact-sensitive plate glass front sheet with a glass fiber-reinforced thermoplastic composite layer. Porcher Industries explained in a LinkedIn post that it was challenging to develop a laminate thin and clear enough for solar cells beneath to function effectively. One key was a glass fiber treatment for improved adhesion with the thermoplastic matrix. Targeted benefits include reduced cost and weight and increased impact resistance to enable a wider range of renewable solar energy applications. JEC World 2022 preview: Porcher Industries “Puzzle-cut” SAERfoam for complex curve drapability, fast assembly Photo Credit: CW at JEC World 202 SAERTEX (Saerbeck, Germany) displayed a variety of products and applications. One of the more eye-catching displays was its SAERfoam-cored wind blade segment featuring its patent-pending “puzzle” pattern for drapability and improved assembly of precut kits. As explained in a June 2021 webinar, SAERfoam does not use a scrim, but instead inserts glass fibers into the foam for improved connection to sandwich skins. The drapable “puzzle” pattern enables conformability to complex curves, which facilitates dry layup for infusion and reduces resin consumption. Larger, dog bone-shaped pieces can be cut and used to quickly secure abutted foam pieces during dry layup. The cut pattern also aids with excellent resin flow and wetout during infusion. Hydrogen tanks proliferate CW has been writing about the impact of the green energy transition on composites, specifically the rapidly growing hydrogen economy’s need for compressed gas and cryogenic liquid hydrogen storage tanks and how that will affect the carbon fiber supply chain. Spoiler alert — the estimated need for millions of tanks by 2030 is already putting a strain on the supply of composite pressure vessels as well as the high-strength carbon fiber they require. Accordingly, hydrogen storage tanks were popular in JEC World 2022 displays: A Type IV compressed gas tank made by MIKROSAM using its automated towpreg winding system for H2storage.nl CW’s recent MIKROSAM webinar. Tank for H2storage.nl made by MIKROSAM using towpreg winding. Photo Credit: CW Type IV compressed gas tanks were displayed by Hanwha Solutions (Seoul, South Korea), which recently acquired composite tank manufacturer Cimarron Composites (Huntsville, Ala., U.S.). Photo Credit: CW Cutaway of Type IV compressed gas tank displayed by engineering firm CIKONI (Stuttgart, Germany) and fiber patch placement (FPP) technology supplier Cevotec (Unterhaching, Germany) in a project that has demonstrated at least 15% material savings by using FPP reinforcement on the tank boss dome to reduce redundant whole tank windings. Photo Credit: CW